{"prompt": "['Improving Physical Function in Sarcoma Survivors', 'Protocol number: eIRB# 19942', 'Version # 4.0', '16 APR 2020', 'PI: Lara Davis, MD', 'a unique ID, username, and password and must complete training appropriate to their role', 'before they are authorized to enter, access, and store data in the database.', 'Survey responses and results of physical function assessments will be entered into the EDC', 'system by study personnel at OHSU. All other electronic data extracts will be stored only on', 'OHSU computers and restricted drives, limited only to study investigators and staff with', 'authorization to access the data. Quality assurance will be conducted as outlined in Section', '10.3, Quality Assurance & Quality Control.', 'Results of some physical function assessments may be shared with participants at the', 'completion of the study.', '11.4 MAINTENANCE OF RECORDS', 'Records and documents pertaining to the conduct of this study, source documents, consent', 'forms, laboratory test results and medication inventory records, must be retained by the', 'Investigator for a period of 2 years, after which all study databases will be de-identified and', 'archived within the Knight Cancer Institute.', 'If the Investigator relocates or for any reason withdraws from the study, the study records must', 'be transferred to an agreed upon designee, such as another institution or another investigator at', 'OHSU. Records must be maintained according to institutional requirements.', '11.5 PUBLICATION AND DATA SHARING POLICY', 'This study will adhere to the requirements set forth by the ICMJE and FDAAA that requires all', 'clinical trials to be registered in a public trials registry (e.g., ClinicalTrials.gov) prior to participant', 'enrollment.', '12. ETHICS/PROTECTION OF HUMAN PARTICIPANTS', '12.1', 'ETHICAL STANDARD', 'The Investigator will ensure that this study is conducted in full conformity with Regulations for', 'the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50,', '21 CFR Part 56, and/or the ICH E6.', '12.2 INSTITUTIONAL REVIEW BOARD', 'The protocol, informed consent form(s), recruitment materials, and all participant materials will', 'be submitted to the IRB for review and approval. Approval of both the protocol and the consent', 'form must be obtained before any participant is enrolled. Any amendment to the protocol will', 'require review and approval by the IRB before the changes are implemented to the study. All', 'changes to the consent form will be IRB approved; a determination will be made regarding', 'whether previously consented participants need to be re-consented.', '12.3', 'INFORMED CONSENT', 'Informed consent will be obtained from all participants, or the legally authorized representative', 'of the participant, participating in this trial, as stated in the Informed Consent section of 21 CFR', '36']['Improving Physical Function in Sarcoma Survivors', 'Protocol number: eIRB# 19942', 'Version # 4.0', '16 APR 2020', 'PI: Lara Davis, MD', 'Part 50. Documentation of the consent process and a copy of the signed consent shall be', \"maintained in the participant's medical record.\", '12.3.1 CONSENT PROCEDURES AND DOCUMENTATION', \"Informed consent is a process that is initiated prior to the individual's agreement to participate in\", \"the study and continues throughout the individual's study participation. Extensive discussion of\", 'risks and possible benefits of participation will be provided to the participants and their families', 'as appropriate. Consent forms will be IRB-approved and provided to the participant in-person or', 'via email, fax, mail or other modality. The participant will be asked to read and review the', 'document. During the consent process, the subject will have access to a copy of the consent', 'form and the consenting investigator or designee will discuss and review the entirety of the', 'consent form with the subject. The Investigator will explain the research study to the participant', 'and answer any questions that may arise. All participants will receive a verbal explanation in', 'terms suited to their comprehension of the purposes, procedures, and potential risks/benefits of', 'the study, alternatives to participation, and of their rights as research participants. Participants', 'will have the opportunity to carefully review the written consent form and ask questions prior to', 'signing. The participants should have the opportunity to discuss the study with their surrogates', 'or think about it prior to agreeing to participate. The participant will sign the informed consent', 'document prior to any procedures being done specifically for the study. The consent form will', 'then be provided in-person, mailed, faxed, emailed, or returned to the site by other modality in', \"its entirety. The consent process will be documented in the participant's health record. Upon\", 'receipt of the signed consent, the investigator or designee who performed the consent will sign', \"and date the consent form and document the consent process in the participant's health record.\", 'The participants may withdraw consent at any time throughout the course of the trial. A copy of', 'the informed consent document will be given to the participants or provided via email, fax mail', 'or other modality for their records. The rights and welfare of the participants will be protected by', 'emphasizing to them that the quality of their medical care will not be adversely affected if they', 'decline to participate in this study.', '12.4', 'PROTOCOL REVIEW', 'The protocol and informed consent form for this study must be reviewed and approved in writing', \"by the OHSU Knight Cancer Institute's Clinical Research Review Committee (CRRC) and the\", 'appropriate IRB prior to any participant being consented on this study.', '12.5 CHANGES TO PROTOCOL', 'Any modification of this protocol must be documented in the form of a protocol revision or', 'amendment submitted by the Investigator and approved by the CRRC and IRB, before the', 'revision or amendment may be implemented. The only circumstance in which the amendment', 'may be initiated without regulatory approval is for a change necessary to eliminate an apparent', 'and immediate hazard to the participant. In that event, the Investigator must notify the IRB (and', 'sponsor/FDA if under an IND/IDE) within 5 business days after the implementation.', '13. REFERENCES', '1.', 'Courneya KS, Friedenreich CM. Physical exercise and quality of life following cancer', 'diagnosis: A literature review. Annals of Behavioral Medicine. 1999;21(2):17', '2.', 'Jager-Wittenaar H, Dijkstra Pieter U, Vissink A, et al. Changes in nutritional status and', 'dietary intake during and after head and neck cancer treatment. Head & Neck.', '37']\n\n###\n\n", "completion": "END"}